Eye injections are the only medication currently available to treat diabetes-related retinopathy. Modern eye injections are not painful and don’t cause many side effects. Diabetic retinopathy affects ...

People with diabetic macular edema may receive eye injections to help control their symptoms. These shots can help to improve vision and also stop the damage that causes vision issues to get worse.

People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...

Hypertensive retinopathy occurs due to high blood pressure, while diabetic retinopathy results from diabetes. Both are eye diseases affecting the retina. Retinopathy is an eye disease affecting the ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...

Diabetic eye disease is a leading cause of vision loss in individuals aged 20 to 74,(3) and diabetic macular edema (DME), left untreated, is the leading cause of blindness in diabetic patients. The ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

While eye drops can help with diabetes-related symptoms, such as dry eyes or irritation, they do not treat the underlying retinopathy. Diabetic retinopathy is a diabetes-related complication that ...

Please provide your email address to receive an email when new articles are posted on . The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third ...

Swelling, leaking blood vessels, or atypical growths can occur in your retina when you develop diabetic retinopathy. Recognizing specific changes can help your doctor diagnose your eye condition ...

SAN FRANCISCO -- A form of gene therapy stabilized or improved diabetic retinopathy (DR) for up to a year, particularly in patients with nonproliferative (NP) DR, a small clinical study showed.